Table 3.
Univariate analyses of clinical and dose-volumetric parameters associated with the risk of radiation-induced liver disease
| Variables | < Grade 2 (%) | ≥ Grade 2 (%) | p-value |
|---|---|---|---|
| Age (years) |
61.7 ± 8.7 |
59.3 ± 11.1 |
0.324 |
| Gender |
|
|
0.323 |
| Male |
61 (83.6) |
12 (16.4) |
|
| Female |
14 (73.7) |
5 (26.3) |
|
| ECOG performance score |
|
|
0.402 |
| 0-1 |
72 (80.9) |
17 (19.1) |
|
| 2 |
3 (100.0) |
0 (0.0) |
|
| Child-Pugh class |
|
|
0.008 |
| A |
59 (88.1) |
8 (11.9) |
|
| B |
16 (64.0) |
9 (36.0) |
|
| Viral etiology |
|
|
0.278 |
| HBs-Ag (+) |
58 (84.1) |
11 (15.9) |
|
| HBs-Ag (-) |
17 (73.9) |
6 (26.1) |
|
| SBRT dose (Gy) |
46.5 ± 9.2 |
43.4 ± 8.8 |
0.200 |
| Fraction size (Gy) |
14.0 ± 2.1 |
13.2 ± 1.9 |
0.124 |
| Normal liver volume (cm3) |
1199.3 ± 251.0 |
1036.5 ± 300.2 |
0.022 |
| GTV (cm3) |
15.9 ± 20.5 |
15.7 ± 12.8 |
0.965 |
| PTV (cm3) |
58.5 ± 53.5 |
54.4 ± 31.0 |
0.761 |
| Mean liver dose (Gy) |
8.6 ± 3.5 |
9.2 ± 4.5 |
0.569 |
| D33%* (Gy) |
8.2 ± 4.7 |
9.3 ± 6.8 |
0.435 |
| D50%† (Gy) |
4.5 ± 3.4 |
5.2 ± 4.6 |
0.494 |
| rV60Gy |
1191.7 ± 249.8 |
1030.5 ± 300.9 |
0.023 |
| rV55Gy |
1188.8 ± 249.8 |
1028.8 ± 301.2 |
0.024 |
| rV50Gy |
1183.5 ± 249.0 |
1026.9 ± 300.9 |
0.027 |
| rV45Gy |
1167.0 ± 244.6 |
1015.6 ± 294.1 |
0.029 |
| rV40Gy |
1153.0 ± 244.8 |
999.7 ± 303.5 |
0.028 |
| rV35Gy |
1133.9 ± 243.8 |
977.1 ± 307.2 |
0.025 |
| rV30Gy |
1114.0 ± 243.1 |
959.4 ± 308.0 |
0.027 |
| rV25Gy |
1086.7 ± 241.3 |
936.1 ± 308.1 |
0.030 |
| rV20Gy |
1045.5 ± 239.0 |
900.0 ± 309.3 |
0.035 |
| rV15Gy |
976.5 ± 237.7 |
835.8 ± 308.0 |
0.040 |
| rV10Gy |
856.6 ± 249.9 |
728.9 ± 310.3 |
0.073 |
| rV5Gy | 655.5 ± 262.8 | 569.4 ± 295.5 | 0.237 |
Abbreviations:ECOG Eastern Cooperative Oncology Group, HBs-Ag hepatitis B surface-antigen, SBRT stereotactic body radiotherapy, GTV gross tumor volume, PTV planning target volume.
*Dose to 33% of the normal liver.
†Dose to 50% of the normal liver.